Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.
blood collection
blood component production
blood donation testing
blood safety
plasma
transfusion medicine
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
23
02
2021
received:
23
12
2020
accepted:
24
02
2021
pubmed:
28
3
2021
medline:
16
10
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
The lack of definitive treatment or preventative options for COVID-19 led many clinicians early on to consider convalescent plasma (CCP) as potentially therapeutic. Regulators, blood centres and hospitals worldwide worked quickly to get CCP to the bedside. Although response was admirable, several areas have been identified to help improve future pandemic management. A multidisciplinary, multinational subgroup from the ISBT Working Group on COVID-19 was tasked with drafting a manuscript that describes the lessons learned pertaining to procurement and administration of CCP, derived from a comprehensive questionnaire within the subgroup. While each country's responses and preparedness for the pandemic varied, there were shared challenges, spanning supply chain disruptions, staffing, impact of social distancing on the collection of regular blood and CCP products, and the availability of screening and confirmatory SARS-CoV-2 testing for donors and patients. The lack of a general framework to organize data gathering across clinical trials and the desire to provide a potentially life-saving therapeutic through compassionate use hampered the collection of much-needed safety and outcome data worldwide. Communication across all stakeholders was identified as being central to reducing confusion. The need for flexibility and adaptability remains paramount when dealing with a pandemic. As the world approaches the first anniversary of the COVID-19 pandemic with rising rates worldwide and over 115 million cases and 2·55 million deaths, respectively, it is important to reflect on how to better prepare for future pandemics as we continue to combat the current one.
Sections du résumé
BACKGROUND
BACKGROUND
The lack of definitive treatment or preventative options for COVID-19 led many clinicians early on to consider convalescent plasma (CCP) as potentially therapeutic. Regulators, blood centres and hospitals worldwide worked quickly to get CCP to the bedside. Although response was admirable, several areas have been identified to help improve future pandemic management.
MATERIALS AND METHODS
METHODS
A multidisciplinary, multinational subgroup from the ISBT Working Group on COVID-19 was tasked with drafting a manuscript that describes the lessons learned pertaining to procurement and administration of CCP, derived from a comprehensive questionnaire within the subgroup.
RESULTS
RESULTS
While each country's responses and preparedness for the pandemic varied, there were shared challenges, spanning supply chain disruptions, staffing, impact of social distancing on the collection of regular blood and CCP products, and the availability of screening and confirmatory SARS-CoV-2 testing for donors and patients. The lack of a general framework to organize data gathering across clinical trials and the desire to provide a potentially life-saving therapeutic through compassionate use hampered the collection of much-needed safety and outcome data worldwide. Communication across all stakeholders was identified as being central to reducing confusion.
CONCLUSION
CONCLUSIONS
The need for flexibility and adaptability remains paramount when dealing with a pandemic. As the world approaches the first anniversary of the COVID-19 pandemic with rising rates worldwide and over 115 million cases and 2·55 million deaths, respectively, it is important to reflect on how to better prepare for future pandemics as we continue to combat the current one.
Identifiants
pubmed: 33772791
doi: 10.1111/vox.13096
pmc: PMC8250874
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
872-879Informations de copyright
© 2021 International Society of Blood Transfusion.
Références
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
JAMA. 2020 Aug 11;324(6):543-545
pubmed: 32717043
Vox Sang. 2021 Jan;116(1):13-14
pubmed: 32464700
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
BMJ. 2020 Oct 19;371:m4057
pubmed: 33077424
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Chest. 2013 Aug;144(2):464-473
pubmed: 23450336
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Blood. 2020 Oct 15;136(16):1888-1891
pubmed: 32871595
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
Transfusion. 2020 Dec;60(12):2938-2951
pubmed: 32935877
Am J Clin Pathol. 2021 Feb 11;155(3):343-353
pubmed: 33155015
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
N Engl J Med. 2021 Jan 14;384(2):191
pubmed: 33264542
Vox Sang. 2006 Aug;91(2):162-73
pubmed: 16907878
N Engl J Med. 2016 Oct 13;375(15):1448-1456
pubmed: 27732819
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 32917729
Blood. 2020 Aug 6;136(6):654-655
pubmed: 32761219
Transfusion. 2021 May;61(5):1447-1460
pubmed: 33604884
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Vox Sang. 2021 Jan;116(1):18-35
pubmed: 32533868
Vox Sang. 2010 Oct;99(3):220-31
pubmed: 20840337
Lancet. 2020 Oct 3;396(10256):959-967
pubmed: 32896292
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
Transfus Med. 2019 Apr;29 Suppl 1:6-12
pubmed: 29148106
Vox Sang. 2021 Jan;116(1):88-98
pubmed: 32542847
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353